Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of MK-2060 with Clopidogrel in ESRD
NCT05335005Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- May 2022
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of MK-2060 in thrombosis, sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience One or More Bleeding Related Adverse Events up to 104 days, Number of Participants Who Experience One or More Adverse Events up to 104 days and 1 more. Started May 2022; status: completed.
02
Drugs
MK-2060
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT05335005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05335005.